Nichi-Iko And Eisai Expand Alliance To China
Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.
You may also be interested in...
Nichi-Iko maintains it is still on course to be one of the very few players to offer an ‘interchangeable’ biosimilar in the US, with its rival to Janssen’s Remicade. The Japanese company has revealed its latest schedule as it also reported full-year financial results.
Despite seeing sales through its US Sagent unit hit by supply issues with CMOs, Nichi-Iko says its US profits have increased on the back of newly-launched products. However, this failed to offset the impact of NHI price revisions in Japan, dragging down profits in the first nine months of the year.
Nichi-Iko is exploring the possibility of a joint venture with digital services provider MedPeer, building on a collaboration that the Japanese generics firm believes will represent a “new generic drugs business model.”